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A B S T R A C T
Background: Pegylated interferon (Peg-ifn) and standard interferon (ifn) play a 
significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard 
ifn is widely available in Brazil for the treatment of HCV infection genotypes 2 or 3, but 
its efficacy compared to Peg-ifn is unknown. 
Objective: To compare the sustained virological response (SVR) rates following treatment 
with biosimilar standard ifn plus ribavirin (RBV) versus Peg-ifn plus RBV in patients with 
HCV genotypes 2 or 3 infection. 
Methods: A retrospective cohort study was conducted in patients with HCV genotypes 2 or 3 
infection treated with biosimilar standard ifn plus RBV or with Peg-ifn plus RBV. SVR rates 
of the two treatments were compared. 
Results: from January 2005 to December 2010, 172 patients with a mean age of 44 +/- 9.3 
years were included. There were eight (4.7%) patients with HCV genotype 2 infections. 
one hundred fourteen (66.3%) were treated with biosimilar standard ifn plus RBV, whist 
58 (33.7%) patients were treated with Peg-ifn plus RBV. Between the two groups, there 
were no significant differences regarding age, gender, glucose level, platelet count, hepatic 
necroinflammatory grade, and hepatic fibrosis stage. overall, 59.3% (102/172) patients had 
SVR. in patients treated with Peg-ifn plus RBV, 79.3% (46/58) had SVR compared to 49.1% 
(56/114) among those treated with biosimilar standard ifn plus RBV (p = 0.0001). 
Conclusion: in patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in 
patients receiving Peg-ifn plus RBV related to patients treated with biosimilar standard 
ifn plus RBV. 
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Introduction
Hepatitis C virus (HCV) infection has a high prevalence 
worldwide and is the leading cause of cirrhosis and 
hepatocellular carcinoma.1,2 The antiviral treatment for 
HCV infection, a combination of interferon α (pegylated or 
non-pegylated) and ribavirin (RBV), reduces liver disease 
progression and improves the quality of life of patients who 
obtain sustained virological response (SVR).3,4 
Among patients with HCV genotype 1 infection, SVR rates 
are higher in those treated with pegylated (Peg) interferon 
(ifn) (pegylated interferon alpha 2a or 2b) plus RBV than in 
those treated with standard ifn (interferon alpha 2a or 2b) 
plus RBV.5,6 However, among patients with HCV genotypes 
2 or 3 infection, some large studies showed no difference in 
SVR rates when patients were treated with Peg-ifn plus RBV 
or with standard ifn plus RBV. it is important to consider 
that the cost of treatment with Peg-ifn is higher than that 
with non-Peg-ifn.
in 2000, according to the national guidelines for hepatitis 
C treatment from the Brazilian Ministry of Health, patients 
with chronic HCV infection became eligible to receive 
antiviral treatment, fully covered by government-funded 
healthcare.7 in 2007, according to a new protocol from 
the Brazilian Ministry of Health, patients with genotype 
1 infection were to be treated with Peg-ifn plus RBV, and 
patients with genotypes 2 or 3 infections should be treated 
with standard ifn plus RBV.8 Since 2000, biosimilar standard 
ifn has been used in Brazil for genotypes 2 or 3 infections. 
The main objective of this study is to compare the SVR rates 
of the biosimilar standard ifn plus RBV with that of Peg-ifn 
plus RBV in patients with HCV genotypes 2 or 3 infections.
Patients and methods
Patient enrollment 
Patients with HVC genotypes 2 or 3 infections, treated for the 
first time with biosimilar standard ifn plus RBV or with Peg-
ifn plus RBV at the Hospital de Clínicas, Universidade Estadual 
de Campinas, state of São Paulo, Brazil from January 2005 to 
December 2010, were included in this study. Chronic hepatitis 
C was defined as the presence of HCV antibody (Abbott 
AxSYM Anti-HCV 3.0, Abbott Laboratories – Wiesbaden, 
Germany) and detectable serum HCV RnA (Amplicor HCV 2, 
Roche Diagnostics Systems inc – Branchburg, USA). Patients 
with HiV infection, detectable hepatitis B surface antigen, 
evidence of other liver disease (e.g., autoimmune hepatitis 
and primary biliary cirrhosis), previous treatment for HCV 
infection, and/or previous therapy with immunosuppressive 
drugs were excluded from the study. 
Patients received Peg-ifn alpha-2a (180 µg) or Peg-ifn 
alpha-2b (1.5 µg/Kg) subcutaneously once a week, or biosimilar 
standard ifn (3 million units) three times a week. All patients 
also received RBV, 1,000 mg to 1,250 mg a day according to the 
patient’s weight. SVR was defined as negative HCV RnA six 
months after treatment.
Data collection
Baseline data were collected from medical records. They 
included demographic information, HCV genotype, and 
liver histological data. Prior to initiation of treatment, serum 
biochemical analyses using commercial tests were carried 
out. These included fasting glucose level and platelet count. 
Amplicons generated by the Amplicor® HCV test were used, 
applying a commercially available assay (Line Probe assay, 
LiPA HCV, innogenetics – Gent, Belgium) to determine HCV 
genotype. 
Histological evaluation
Hepatic histological evaluation was graded and staged 
according to the Metavir scoring system.9 The Metavir score 
incorporates five progressive stages of fibrosis, f0 (absence of 
fibrosis) to f4 (cirrhosis), and four grades of necroinflammatory 
activity, A0 (no activity) to A3 (severe activity), taking into 
account the severity of portal and lobular necroinflammatory 
lesions. for analysis purposes, the diagnosis of cirrhosis was 
made upon histological examination (f4 stage) or by the 
combination of clinical and laboratorial parameters (presence 
of hyperbilirrubinemia, esophageal varices, ascites, and 
splenomegaly). 
Statistical analysis
Continuous variables were analyzed as mean and standard 
deviation, and categorical variables as frequency, unless 
otherwise stated. Study patients were categorized into 
biosimilar standard ifn or Peg-ifn groups. Analysis of variance 
(standard or nonparametric, as appropriate) was used for 
continuous variables whereas the chi-square test was used 
for categorical variables. All analyses were performed with Epi 
info software version 3.5.1. (Centers for Disease Control – Atlanta, 
GA, USA). A significance level of 5% (p < 0.05) was considered 
statistically significant.
Results 
Pretreatment demographic and clinical characteristics 
A total of 172 patients were included in the study. Patients’ 
characteristics are presented in Table 1: 71% were male, and 
the median age at the beginning of follow up was 44 years 
(range: 17-69). only eight (4.7%) patients were infected by HCV 
genotype 2.
Liver biopsy was performed in 158 patients. fibrosis was 
staged as f1 or f2 in 95 (55.2%) patients, and as f3 or f4 
in 77 (44.8%). in 14 patients, the diagnosis of cirrhosis (f4) 
was based on clinical and laboratorial parameters alone. 
Histological analysis showed necroinflammatory grade as no 
activity (A0) or mild (A1) in 27 (17.1%) patients, and moderate 
(A2) or severe (A3) in 131 (82.9%). 
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Patients’ characteristics in Peg-ifn plus RBV and biosimilar 
standard ifn plus RBV treatment groups were similar (Table 2). 
There were no significant differences between the two groups 
in respect to demographic characteristics, fast glucose level and 
platelet count. Similarly, the number of patients with genotype 2 
infection, advanced fibrosis (f3 or f4), and cirrhosis were similar 
in the two treatment groups. The only significant difference 
was body weight: patients treated with biosimilar standard ifn 
plus RBV had a higher body weight when compared with those 
treated with Peg-ifn plus RBV (p = 0.03).
Treatment
fifty-eight (33.7%) patients were treated with Peg-ifn plus 
RBV, and 114 (66.3%) with biosimilar standard ifn 
plus RBV. out of 172 patients, 157 received Peg-ifn plus 
RBV or biosimilar standard ifn plus RBV for 24 weeks. Ten 
patients received Peg-ifn plus RBV for 48 weeks. Treatment 
was discontinued in five (3%) patients, three (5.2%) in 
Peg-ifn plus RBV treated group with, and two (1.8%) 
in the group treated with biosimilar standard ifn plus 
RBV (p = 0.2). The dose of ifn or Peg-ifn was reduced in 
nine (5.2%) patients; this reduction was more frequent 
in patients treated with Peg-ifn plus RBV than in those 
treated with biosimilar standard ifn plus RBV, in six 
(10.3%) and three (2.6%) patients, respectively (p = 0.03). 
The dose of RBV was reduced in 13 (7.6%) patients; it was 
more frequent in patients treated with Peg-ifn plus RBV 
than in those treated with biosimilar standard ifn plus 
RBV, in eight (13.8%) and five (4.4%) patients, respectively 
(p = 0.02).
Virological response
of 172 patients treated for 24 or 48 weeks, 102 (59.3%) patients 
had SVR. There was an association between receiving Peg-
ifn plus RBV and having SVR. Among patients treated with 
Peg-ifn plus RBV, 79.3% (46/58) had SVR, in contrast, in patients 
who were treated with biosimilar standard ifn plus RBV, 49.1% 
(56/114) had SVR (p = 0.0001). When considered only patients 
treated for 24 weeks, among patients treated with Peg-ifn plus 
RBV, 79.2% (38/48) had SVR; and in patients who were treated 
with biosimilar standard ifn plus RBV, 49.1% (56/114) had SVR 
(p = 0.0004).
Characteristic Value*
Male – n (%) 123 (71.5%)
Age (years) 44.0 ± 9.3 
Weight (kg) 71.0 ± 14.2 
Glucose (mg/dL) 85.0 ± 18.8
Platelets (x 109/L) 171.0 ± 70.8 
Genotype 2 – n (%) 8 (4.7%)
necroinflammatory grade1 – n (%)
 A0 / A1 27 (17.1%)
 A2 / A3 131 (82.9%)
fibrosis stage – n (%)
 f1 / f2 95 (55.2%)
 f3 / f4 77 (44.8%)
Cirrhosis – n (%) 41 (23.8%)
*Data presented as mean and standard deviation, unless otherwise 
noted; 1available for 158 patients.
Table 1 - Characteristics of 172 study patients with 
chronic hepatitis C virus infection (January 2005–
December 2010) 
Variable* Peg-IFN (2a or 2b) + RBV  
(n = 58)
Biosimilar standard IFN + RBV  
(n = 114)
p-value 
Male – n (%) 36 (62.1%) 87 (76.3%) 0.05
Age (years) 50.0 ± 9.7 42.0 ± 8.3 0.16
Weight (kg) 70.0 ± 14.0 72.0 ± 14.0 0.03
Glucose (mg/dL) 84.0 ± 9.3 87.0 ± 21.9 0.07
Platelets (x 109/L) 170.0 ± 67.1 172.0 ± 72.8 0.77
Genotype 2 – n (%) 1 (1.7%) 7 (6.1%) 0.19
necroinflammatory grade1 – n (%)
 A0 / A1 9 (16.4%) 18 (17.5%) 0.85
 A2 / A3 46 (83.6%) 85 (82.5%) 0.85
fibrosis – n (%)
 f1 / f2 33 (56.9%) 62 (54.4%) 0.75
 f3 / f4 25 (43.1%) 52 (45.6%) 0.75
Cirrhosis – n (%) 12 (20.7%) 29 (25.4%) 0.48
Peg-ifn, pegylated interferon; RBV, ribavirin; ifn, interferon. *Data presented as mean and standard deviation, unless otherwise noted; 
1available for 158 patients.
Table 2 - Univariate analysis of pretreatment characteristics of patients treated with Peg-IFN plus RBV or IFN plus RBV
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Among patients with stage 1 or 2 fibrosis, in comparison 
to biosimilar standard ifn plus RBV Peg-ifn plus RBV was 
associated with significantly more SVR (p = 0.01) (fig. 1). The 
same was observed among patients with stage 3 or 4 fibrosis 
(p = 0.003) (fig. 1). 
other studies have shown no consistent advantage of Peg-
ifn over standard ifn in patients with viral genotypes 2 or 3 
infections.5,6,14 in addition, although the SVR rate found in the 
present study among patients treated with Peg-ifn is similar to 
that of previous studies, it is lower in the non-Peg-ifn treated 
group. The reason for this finding is unknown. 
Biosimilar Peg-ifn is not available, the only Peg-ifn 
formulations currently available are Peg-ifn alpha-2a 
(Pegasys®) or alpha-2b (Peg intron®). Therefore, the Peg-ifn 
used in this study are the same formulations used in studies 
reported in the literature. However, with respect to standard 
ifn, there are several biosimilar formulations available. in the 
present study, patients were treated with biosimilar standard 
ifn, and the high SVR rates of ifn reported in previous studies 
were the original trademark.5,6,13,14 
in Brazil, previous studies in patients with genotype 2 
or 3 treated with biosimilar standard ifn plus RBV showed 
SVR rates ranging from 39 to 46%, similar to that found in 
the present study.15-17 on the other hand, one Brazilian 
study on patients with genotypes 2 or 3 infections who were 
treated with Peg-ifn plus RBV found a SVR rate of 67%.18 
Biosimilar standard ifn plus RBV treatment is routinely used 
in Brazilian patients with genotype 2 or 3 infections and, 
according the present study findings, it was less effective 
regarding SVR than what would be expected according to 
the literature. 
The present study has some limitations. Due to retrospective 
nature of this study, some patients were treated for more 
than 24 weeks, and levels of HCV RnA were not available. in 
addition, it was not possible to randomize patients. However, 
this study provides an important clinical data in real life 
practice, and to the authors’ best knowledge, it is the first 
comparative study of biosimilar standard ifn and Peg-ifn for 
HCV genotypes 2 or 3 infections.
in conclusion, regarding the SVR rate among the studied 
patients, Peg-ifn plus RBV was better than biosimilar standard 
ifn for genotype 2 or 3 infections regardless of fibrosis stage, 
and the SVR rate associated with biosimilar standard ifn was 
low. Therefore, Peg-ifn is a better option for genotype 2 or 3 
infections than biosimilar standard ifn.
Conflict of interest
 All authors declare to have no conflict of interest.
R E f E R E n C E S
 1. Kim WR, Brown RS Jr, Terrault nA, El-Serag H. Burden of 
liver disease in the United States: summary of a workshop. 
Hepatology. 2002;36:227-42.
 2. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf 
TL. Trends in health care resource use for hepatitis C virus 
infection in the United States. Hepatology. 2005;42:1406-13.
 3. Bini EJ, Mehandru S. Sustained virological response rates and 
health-related quality of life after interferon and ribavirin 
therapy in patients with chronic hepatitis C virus infection 
and persistently normal alanine aminotransferase levels. 
Aliment Pharmacol Ther. 2006;23:777-85.
Fig. 1 - Sustained virological response according to stage 
of liver fibrosis. SVR, sustained virological response; IFN, 
interferon; Peg-IFN, pegylated interferon.
Pe
rc
en
t 
of
 p
at
ie
n
s 
w
it
h
 S
V
R
f1/f2 f3/f4
 Stage of liver fibrosis
90
80
70
60
50
40
30
20
10
0
p = 0.01
82
56
39
76
p = 0.003
Biosimilar standard ifn
Peg-ifn
Discussion
in the present study, Peg-ifn plus RBV was significantly more 
effective than biosimilar standard ifn plus RBV for treating 
patients with HCV genotypes 2 or 3 infection, irrespective of 
fibrosis stage. According to the present findings, although 
the presence of advanced fibrosis (f3 or f4) is associated with 
lower SVR rates than those with mild or moderate fibrosis (f1 
or f2), both groups of patients benefited from being treated 
with Peg-ifn plus RBV.10
Both ifn and RBV doses have a major impact on SVR rates. 
Patients who receive the optimal dose of Peg-ifn or standard 
ifn and RBV for the planned duration have higher rates of SVR 
than those who require dosage reductions.11 Although RBV and 
ifn dosage reduction were more frequent in patients treated 
with Peg-ifn and RBV than those treated with biosimilar 
standard ifn and RBV, SVR rate was higher in the Peg-ifn 
group.
overall, the rate of SVR found in this study was similar 
to that reported with Peg-ifn plus RBV in patients with HCV 
genotypes 2 or 3 infection. Studies have shown SVR rates 
ranging from 76% to 81%, and in the current study the SVR rate 
was 79.3%.5,6,12 in contrast to previous reports, that showed 
SVR rates ranging from 61% to 79% in patients with genotype 
2 or 3 infection treated with standard ifn plus RBV, a SVR rate 
of 49.1% was found in this study.5,6,13
236 BRAZ J INFECT DIS. 2012;16(3):232-236
 4. Poynard T, McHutchison J, Manns M, et al. impact of 
pegylated interferon alfa-2b and ribavirin on liver fibrosis 
in patients with chronic hepatitis C. Gastroenterology. 
2002;122:1303-13.
 5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon 
alfa-2b plus ribavirin compared with interferon alfa-2b 
plus ribavirin for initial treatment of chronic hepatitis C: a 
randomised trial. Lancet. 2001;358: 958-65.
 6. fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-
2a plus ribavirin for chronic hepatitis C virus infection.  
n Engl J Med. 2002;347:975-82.
 7. Ministério da Saúde (Brasil). Portaria 639. Anexo i: Protocolo 
clínico e diretrizes terapêuticas da hepatite viral crônica tipo 
C. Diário oficial da União, Df, 26 jun 2000. p. 34.
 8. Clinical guidelines for hepatitis C 2007, Dispõe sobre o 
Protocolo Clínico e Diretrizes Terapêuticas para Hepatite 
Viral C. 2007. Report nº: Portaria nº 34, de 28 de setembro de 
2007; iD6065503-0. Brasil: Ministério da Saúde. Secretaria de 
Vigilância em Saúde. Departamento de DST AeHVPn.
 9. Bedossa P, Poynard T. The METAViR cooperative study group. 
An algorithm for the grading of activity in chronic hepatitis 
C. Hepatology. 1996;24:289-293.
10. Ge D, fellay J, Thompson AJ, et al. Genetic variation in iL28B 
predicts hepatitis C treatment-induced viral clearance. 
nature. 2009;461:399-401.
11. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey 
J, Albrecht J. Early virologic response to treatment with 
peginterferon alfa-2b plus ribavirin in patients with chronic 
hepatitis C. Hepatology. 2003;38:645-52.
12. Jacobson iM, Brown RS Jr, freilich B, et al. Peginterferon 
alfa-2b and weight-based or flat-dose ribavirin in chronic 
hepatitis C patients: a randomized trial. Hepatology. 
2007;46:971-81.
13. Khokhar n. Effectiveness of 48 weeks interferon alfa-2b in 
combination with ribavirin as initial treatment of chronic 
hepatitis. J Ayub Med Coll Abbottabad. 2002;14:5-8.
14. Rumi MG, Aghemo A, D’Ambrosio R, et al. Lack of rapid 
virological response predicts interferon-alpha2b/ribavirin 
therapy failure in HCV genotype 2 patients: a single-centre 
study. Antivir Ther. 2007;12:1033-40.
15. Acras Rn, Pedroso ML, Caum LC, Pisani JC, Amarante 
HM, Carmes ER. The sustained response rates for chronic 
hepatitis C patients undergoing therapy with the several 
interferons and ribavarins supplied by Brazilians Health 
Ministry is comparable to those reported in the literature. 
Arq Gastroenterol. 2004;41:3-9.
16. Alves AV, de Azevedo AP, Perin C, et al. interferon-alpha and 
ribavirin therapy on chronic hepatitis C virus infection: the 
experience of Rio Grande do Sul State Health Department, 
Brazil. Arq Gastroenterol. 2003;40:227-32. 
17. Parise ER, de oliveira AC, Conceição RD, Amaral AC, Leite K. 
Response to treatment with interferon-alpha and ribavirin 
in patients with chronic hepatitis C virus genotypes 2 and 3 
depends on the degree of hepatic fibrosis. Braz J infect Dis. 
2006;10(2):78-81.
18. Gonçales Jr fL, Vigani A, Gonçales n, et al. Weight-based 
combination therapy with peginterferon alpha-2b and 
ribavirin for naïve, relapser and non-responder patients with 
chronic hepatitis C. Braz J infect Dis. 2006;10:311-6.
